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Apoptosisc-Jun N-terminal kinase (JNK) is a stress-activated mitogen-activated protein kinase that plays a central role in
initiating apoptosis in disease conditions. Recent studies have shown that mitochondrial JNK signaling is partly
responsible for ischemic myocardial dysfunction; however, the underlying mechanism remains unclear. Here
we report for the ﬁrst time that activation of mitochondrial JNK, rather than JNK localization on mitochondria,
induces autophagy and apoptosis and aggravates myocardial ischemia/reperfusion injury. Myocardial ischemia/
reperfusion induced a dominant increase of mitochondrial JNK phosphorylation, while JNK mitochondrial local-
ization was reduced. Treatment with Tat-SabKIM1, a retro-inverso peptide which blocks JNK interaction with mi-
tochondria, decreased mitochondrial JNK activation without affecting JNK mitochondrial localization following
reperfusion. Tat-SabKIM1 treatment reduced Bcl2-regulated autophagy, cytochrome c-mediated apoptosis and
myocardial infarct size. Notably, selective inhibition of mitochondrial JNK activation using Tat-SabKIM1 produced
a similar infarct size-reducing effect as inhibiting universal JNK activation with JNK inhibitor SP600125. More-
over, insulin-treated animals exhibited signiﬁcantly dampenedmitochondrial JNK activation accompanied by re-
duced infarct size and diminished autophagy and apoptosis following reperfusion. Taken together, these ﬁndings
demonstrate that mitochondrial JNK activation, rather than JNK mitochondrial localization, induces autophagy
and apoptosis and exacerbatesmyocardial ischemia/reperfusion injury. Insulin selectively inhibitsmitochondrial
JNK activation, contributing to insulin cardioprotection against myocardial ischemic/reperfusion injury. This ar-
ticle is part of a Special Issue entitled: Autophagy and protein quality control in cardiometabolic diseases.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
c-Jun N-terminal kinase (JNK) is a member of an evolutionarily con-
served subfamily of mitogen-activated protein kinases (MAP kinases),
which is critical for cellular responses to a variety of environmental
and cellular stimuli [1,2]. Analysis of JNK-regulated pathways hasoxidase; JNK, c-Jun N-terminal
systolic pressure; MABP, mean
mTOR, mammalian target of
dUTP nick end labeling
y and protein quality control in
and Department of Cardiology,
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gy, The Fourth Military Medical
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mmu.edu.cn (F. Gao).shown that JNK is indispensable for both cell proliferation and apopto-
sis, dependent on the stimuli and the cell type involved [3,4]. In a variety
of pathological conditions, JNK activation has been observed to have a
central role in both extrinsic and intrinsic pathways that initiate apopto-
sis [5]. Inhibition of JNK signaling has been shown to attenuate apopto-
sis in several cell types, including hepatocytes, endothelial cells and
cardiomyocytes, under different conditions [6–8].
Upon activation, the phosphorylated JNK translocates to the nucleus
resulting in apoptosis by increasing the expression of pro-apoptotic
genes through the transactivation of c-Jun/AP1-dependent or p53/73
protein-dependent mechanisms [5]. Recently, a new subcellular loca-
tion of JNKhas been identiﬁed inmitochondria [9]. At themitochondrial
outer membrane, JNK can interact with and phosphorylate a scaffold
protein, Sab, facilitating JNK's translocation to mitochondria for signal-
ing events [9,10]. Mitochondrial translocation of JNK has been present-
ed in cellular and animal levels in the studies of DNA damage, liver
injury, ischemia and oxidative stress [11–13], which are responsive to
decreasedmitochondrial function, such as bluntedmitochondrial respi-
ration, inhibited mitochondrial substrate ﬂux, enhanced production
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apoptosis [14]. These studies establish that mitochondria are a primary
target of pro-apoptotic signaling by JNK.
It has been well documented that JNK signaling is involved in the
induction of cardiac ischemia/reperfusion (I/R) injury [15–17], and inhi-
bition of JNK activation using either genetic modulation or chemical
inhibitors has been shown to protect cardiomyocytes against I/R injury
both in vivo and in vitro [7,18]. A recent study by LoGrasso and
colleagues showed that inhibition of mitoJNK signaling alone, via
disrupting the JNK/sab interaction at the outer mitochondrial mem-
brane using a newly developed biochemical probe, improved mito-
chondrial function and exerted cardioprotective effect similar to that
afforded by universal JNK inhibition, indicating a pivot role of mitoJNK
in the induction of cardiac injury following I/R [19].
Most studies onmechanisms responsible for I/R-induced cardiac ab-
normalities have been focused on necrosis and apoptosis. Until recently
dysregulated autophagy has been shown to play a unique role in I/R in-
jury and post-infarction cardiac remodeling [20]. It has been reported
that autophagic ﬂux triggered by ischemia at the early stage of I/R
may be beneﬁcial, whereas excessive autophagy during reperfusion at
later stage of I/R is harmful [21,22]. Here, we report our ﬁndings that
mitoJNK activation rather than JNK mitochondrial localization induces
autophagy and apoptosis, consequently aggravating myocardial I/R
injury.2. Materials and methods
2.1. Experimental protocol
The experiments were performed in adherence with the National
Institutes of Health Guidelines for the Use of Laboratory Animals and
were approved by the Fourth Military Medical University Committee
on Animal Care. Male Sprague–Dawley rats weighting 180–220 g were
fasted overnight and anesthetized through intraperitoneal injection of
60 mg/kg pentobarbital sodium. Myocardial ischemia was produced
by exteriorizing the heart with a left thoracic incision followed by mak-
ing a slipknot (6–0 silk) around left anterior descending coronary artery,
as described previously [23]. The success in coronary occlusionwas con-
ﬁrmed by immediate ST elevation on electrocardiogram. The animals
were subjected to 30 min of coronary occlusion followed by 2 h of
reperfusion.
The effects of insulin (60 U/l, intravenous infusion at 4 ml/kg/h
for 2 h, beginning at 5 min before reperfusion) on myocardial I/R
injury were examined in I/R + insulin rats. SP600125 (1 mg/kg,
Sigma-Aldrich Co.) and anisomycin (0.1 mg/kg, Sigma-Aldrich Co.)
were administered through femoral vein at 10 and 15 min respec-
tively before reperfusion. Hearts were excised at 2 h after reperfu-
sion and the tissue from the area at risk was separated, washed by
ice-cold saline and then rapidly frozen in liquid nitrogen. The frozen
hearts were stored in a refrigerator at −80 °C while waiting for
Western blot analysis.2.2. Tat-Sab treatment
Tat-scramble (LPSVFGDVGAPSRLPEVSLSPPRRRQRRKKRG-NH2)
and Tat-SabKIM1 (GFESLSVPSPLDLSGPRVVAPPRRRQRRKKRG-NH2)
were purchased from NeoPeptide. Direct injections (ﬁve 5-μl injec-
tions, 2 mg/kg) were delivered 5 min before reperfusion into the
left ventricle wall in areas below the occlusion site of the ligation
(four injections) and in the apex of the heart (one injection), as de-
scribed previously [19]. Injections were made with a 30-gauge needle
and a 10-μl syringe. Control groups subjected to the same I/R procedure
included I/R+ saline, I/R+Tat-scramble and a shamgroupwithout left
anterior descending coronary artery occlusion.2.3. Preparation of mitochondrial and cytosolic/nuclear fractions
Cardiacmitochondriawere isolated from either sham-operated or I/R
rats as described previously [19]. Brieﬂy, rat hearts were washed with
ice-cold isolation buffer (210 mM mannitol, 70 mM sucrose, 5 mM
HEPES, 1 mM EGTA and 0.5 mg/ml BSA, pH 7.4), minced into small
pieces, and then homogenized. The homogenate was centrifuged at
4 °C for 10 min at 1000 g. The supernatant was collected and further
centrifuged at 4 °C for 10 min at 10,000 g. The pellet was re-suspended
in lysis buffer for Western blot analysis of mitochondrial proteins, and
the resulting supernatantwas used as the soluble cytosolic/nuclear frac-
tion. Cytochrome c oxidase IV (COX IV) was used as an internal control
for mitochondria and GAPDH as an internal control for cytosol.
2.4. Determination of myocardial infarct size and apoptosis
At the end of the 2 h reperfusion, myocardial infarct size was deter-
mined by means of a double-staining technique and was analyzed by a
digital imaging system described previously [23]. Myocardial apoptotic
index was analyzed by TUNEL (terminal deoxynucleotidyl nick end la-
beling) assay using an In Situ Cell Death Detection Kit (RocheMolecular
Biochemical, Indianapolis, IN) according to the protocol provided by the
manufacturer; TUNEL staining for apoptotic cell nuclei and DAPI stain-
ing for all myocardial cell nuclei. Cardiomyocytes from four slides per
block which were randomly selected were evaluated to determine the
number and percentage of cells exhibiting positive staining for apo-
ptosis. The apoptosis index (AI) was determined [(no. of apoptotic
myocytes / total no. of myocytes counted) × 100%].
2.5. Assessment of cardiac function
Cardiac function was monitored at the end of the 2 h reperfusion. An
artery microcatheter was intubated into the left ventricle to determine
the left ventricular pressure (LVP). Electrocardiogram, heart rate and
LVP were recorded on a hemodynamic analyzing system (Chengdu In-
strument Co., China). Left ventricular systolic pressure (LVSP), mean arte-
rial blood pressure (MABP) and the instantaneous ﬁrst derivation of LVP
(+dP/dtmax and−dP/dtmax) were obtained by computer algorithms.
2.6. Determination of plasma lactate dehydrogenase levels
Blood samples were drawn at the end of the 2 h reperfusion. Plasma
lactate dehydrogenase (LDH) levelsweremeasuredusing commercial de-
tection kits (DU 640; Beckman Coulter, Brea, CA) according to the
manufacturer's instruction. Allmeasurementswere assayed in duplicates.
2.7. Western blot analysis
Theprotein expression andphosphorylation levelswere determined
usingWestern blot as described previously [23]. The immunoblots were
probedwith anti-JNK, anti-p-JNK (Thr183/Tyr185 Cell Signaling Technol-
ogy, USA), anti-COX IV, anti-cytochrome c (Cell Signaling Technology,
USA), anti-LC3, anti-p62, anti-Beclin1, anti-Bcl2 (Santacruz Biotechnolo-
gy, Inc, USA) and anti-GAPDH (Abcam, USA) antibodies overnight at
4 °C and subsequently incubated with the corresponding secondary anti-
bodies at room temperature for 1 h. The blots were visualized with
ChemiDocXRS (Bio-Rad Laboratory, Hercules, CA). GAPDH was used as
the internal loading control.
2.8. Statistical analysis
All values are presented asmean±SEM. Differenceswere compared
with ANOVA followed by Bonferroni post hoc test. Probabilities of b0.05
were considered to be statistically signiﬁcant. All of the statistical
tests were performed with the GraphPad Prism software, version
5.0 (GraphPad Software Inc., San Diego, CA).
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3.1. I/R induced mitoJNK activation
To elucidate the role of mitoJNK signaling in I/R injury, the localiza-
tion and activation of JNK were determined after reperfusion. Western
blotting of JNK and p-JNK showed two immunoreactive bands withFig. 1.Mitochondrial JNK activation is associatedwith I/R injury. A, representativeWestern blots
(B), JNK/COX IV (C) and p-JNK/JNK (D) inmitochondria following I/R. E, as in A, for cytosol/nuc
cytosol/nucleus following I/R. I, as in A, for total extract. J–K, as in G–H, for total extract. A–K, tr
fusion) restored JNK activation and localization in both mitochondria and cytosol/nucleus. Datapproximate molecular weights of 46- and 55-kDa (Fig. 1A, E, I)
in cytosol/nucleus, while the 55-kDa splice of JNKwas dominant inmito-
chondria, which is consistent with previous studies [19,24]. The phos-
phorylation level of JNK was increased in both mitochondria (Fig. 1A,
B) and cytosol/nucleus (Fig. 1E, F) after 2 h of reperfusion. However, it
should be noted that total JNK in mitochondria was decreased (Fig. 1C)
and total JNK in cytosol/nucleus was increased (Fig. 1G), indicating JNKof p-JNK and JNK inmitochondria following I/R. B–D, the normalized ratio of p-JNK/COX IV
leus. F–H, the normalized ratio of p-JNK/GAPDH (F), JNK/GAPDH (G) and p-JNK/JNK (H) in
eatment with insulin (60 U/l, 4 ml/kg/h for 2 h through femoral vein 5 min before reper-
a are expressed as mean ± SEM. n = 6/group. *P b 0.05, **P b 0.01.
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A dominant JNK activation occurred in mitochondria as evidenced by
the fact that p-JNK/JNK displayed an approximately 4-fold increase in
mitochondria (Fig. 1D) and 2-fold increase in cytosol/nucleus (Fig. 1H).
Consistent with JNK activation in mitochondria and cytosol/nucleus,
universal JNK activation displayed an approximately 4-fold increase
(Fig. 1K), and I/R had little effect on universal JNK expression (Fig. 1J).
To further examine the role ofmitoJNK signaling in I/R injury, insulin
treatment which has been demonstrated by our laboratory and others
as one of the most promising strategies in cardioprotection against I/R
injury was employed [25–29]. As shown previously, insulin treatment
(60U/l, intravenous infusion at 4 ml/kg/h for 2 h, beginning at 5min be-
fore reperfusion) exerted protective effect against I/R injury as evi-
denced by reduced lesion area (Fig. 3A) and plasma LDH
concentration (Fig. 3B). Meanwhile, insulin treatment decreased both
mitochondrial and cytosolic/nuclear JNK activation (Fig. 1B, F). Impor-
tantly, treatment with insulin decreased the ratio of p-JNK/JNK in mito-
chondria, but had little effect on the ratio of p-JNK/JNK in cytosol/
nucleus (Fig. 1D), indicating that insulin could selectively inhibit
mitoJNK activation during reperfusion. In addition, treatmentwith insu-
lin restored the JNK localization after reperfusion (Fig. 1C, G). These re-
sults suggested that I/R-induced JNK activation, especially mitoJNK
activation, is associated with I/R injury.
3.2. InhibitingmitoJNK activationwith Tat-SabKIM1 peptide exerted protective
effect against I/R injury
To examine the role of mitoJNK activation in I/R injury, we used a
peptide containing 20 residues of the SabKIM1 domain along with a
HIV-Tat sequence (Tat-SabKIM1) as described previously [19], which
can be used to block JNK translocation to mitochondria in vivo. It has
been reported that Tat-SabKIM1 does not affect JNK-mediated nuclear
events and JNK translocation to the nucleus [14]. As shown in Fig. 2A,Fig. 2. Inhibiting mitoJNK activation with Tat-SabKIM1 peptide during I/R in vivo. A, representa
injection (2 mg/kg, delivered 5min before reperfusion). B–D, the normalized ratio of p-JNK/COX
E, as in A, for cytosol/nucleus. F–H, the normalized ratio of p-JNK/GAPDH (F), JNK/GAPDH (G) a
mean ± SEM. n = 6/group. *P b 0.05, **P b 0.01.Tat-SabKIM1 injection (2 mg/kg, delivered 5min before reperfusion) de-
creased the phosphorylation level of JNK in mitochondria (Fig. 2B, D),
and had no evident effect on cytosolic/nuclear JNK activation (Fig. 2E,
F, H) following I/R. Unexpectedly, Tat-SabKIM1 injection had no evident
effect on JNK localization following reperfusion (Fig. 2C, G). These re-
sults indicated that injection with Tat-SabKIM1 can speciﬁcally inhibit
mitoJNK activation without impact on cytosolic/nuclear JNK activation
and JNK localization.
Importantly, Tat-SabKIM1 injection markedly reduced lesion area
(Fig. 3A) and plasma LDH level (Fig. 3B) following I/R, exerting similar
cardioprotective effect as treatmentwith insulin (Fig. 3A, B). In addition,
assessment of cardiac function after 2 h of reperfusion revealed that in-
jection with Tat-SabKIM1 increased LVSP (Fig. 3C) and ±LV dP/dtmax in
rats (Fig. 3D, E), while no signiﬁcant differences in MABP and heart
rate have been detected (data not shown). These results suggested
that inhibition ofmitoJNK activation alone exerts cardioprotective effect
against I/R injury.
3.3. mitoJNK activation contributed to Bcl2-regulated autophagy
Next, we examined the effect of mitoJNK activation on autophagy
after reperfusion. I/R resulted in biochemical evidence of cardiacmuscle
autophagy, including conversion of the non-lipidated form of LC3, LC3-I,
to the autophagosomemembrane-associated lipidated form, LC3-II, and
degradation of the autophagy substrate protein p62 (Fig. 4A, B, C). Bcl2
inhibits autophagy through a direct interactionwith the autophagy pro-
tein Beclin1 [30]. I/R-induced autophagy was further conﬁrmed by in-
creased Beclin1 and decreased Bcl2 after reperfusion (Fig. 4A, D, E).
Inhibition of mitoJNK activation through either Tat-SabKIM1 injection
or insulin treatment alleviated I/R-induced autophagy, as evidenced
by the restored levels of LC3-II/LC3-I, p62, Bcl2 and Beclin1 (Fig. 4A, B,
C, D, E). These results indicated that mitoJNK activation triggers the
Bcl2-regulated autophagy following reperfusion.tive Western blots of p-JNK and JNK in mitochondria following I/R with Tat-SabKIM1 (TS)
IV (B), JNK/COX IV (C) and p-JNK/JNK (D) inmitochondria following I/Rwith TS injection.
nd p-JNK/JNK (H) in cytosol/nucleus following I/R with TS injection. Data are expressed as
Fig. 3. Inhibiting mitoJNK activation with Tat-SabKIM1 peptide and treatment with insulin exert protective effect against I/R injury in vivo. A–E, treatment with Tat-SabKIM1 (TS) or insulin
decreasedmyocardial infarct size (INF) expressed as percentage of area at risk (AAR) (A) and plasma lactate dehydrogenase (LDH) concentration (B), and increased left ventricular systolic
pressure (LVSP) (C), and ±dP/dtmax (D, E) following I/R. Data are expressed as mean ± SEM. n = 6/group. *P b 0.05, **P b 0.01.
Fig. 4. Inhibition of mitoJNK activation through insulin or Tat-SabKIM1 treatment ameliorates Bcl2-regulated autophagy following I/R. A, representative Western blots of the following
autophagy-related proteins in heart subjected to I/R with insulin or Tat-SabKIM1 (TS) treatment: LC3-I, LC3-II, p62, Beclin1, and Bcl2. B–E, The statistical results of LC3-II/LC3-I (B), p62
(C), Beclin1 (D) and Bcl2 (E). Data are expressed as mean ± SEM. n = 6/group. *P b 0.05, **P b 0.01.
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As shown in Fig. 5A, the amount of cytochrome c release frommi-
tochondria into the cytosol following I/R displayed an approximately
3-fold increase compared with that in sham group. Treatment with
insulin reduced cytochrome c release into the cytosol by 48.3% (Fig. 5A),
and Tat-SabKIM1 injection alleviated cytochrome c release by 68.9%
(Fig. 5A). Inhibition of mitoJNK signaling through either Tat-SabKIM1 in-
jection or insulin treatment decreases I/R-induced cytochrome c release
from mitochondria.
Next, we examined cardiac apoptosis using TUNEL staining to fur-
ther examine the role ofmitoJNK signaling in the induction of apoptosis.
TUNEL-positive cells were increased in I/R rats (Fig. 5B). Treatmentwith
insulin exerted a signiﬁcant anti-apoptotic effect as evidenced by re-
duced TUNEL-positive staining (Fig. 5B). Meanwhile Tat-SabKIM1 injec-
tion also decreased TUNEL-positive staining, exerting cardioprotective
effect similar to insulin treatment (Fig. 5B). These results indicated
that mitoJNK signaling triggers the mitochondria-mediated apoptosis
following I/R.3.5. Inhibiting mitoJNK activation alone exerted similar cardioprotective
effect as universal JNK inhibition
It's reported that inhibition of universal JNK activation also exerts
cardioprotective effect against I/R injury [7]. Next, we inhibited univer-
sal JNK activation to test the contribution of mitoJNK activation in the
induction of I/R injury. The phosphorylation level of JNK displayed an
approximately 3.5-fold increase after 2 h of reperfusion (Fig. 6A). To fur-
ther elucidate the involvement of JNK in the induction of I/R-induced
myocardium injury, SP600125, a selective JNK inhibitor, was used.
Treatment with SP600125 (1 mg/kg, administered through femoral
vein 10min before reperfusion) decreased phosphorylation level of uni-
versal JNK by 71.4%, and reduced lesion area by 40.3% and plasma LDHFig. 5. Inhibition ofmitoJNK activation through insulin or Tat-SabKIM1 treatment amelioratesmit
normalized to sham group) in rats subjected to I/R with insulin or Tat-SabKIM1 (TS) treatment.
staining in heart slices from rats subjected to I/R. TUNEL positive cells (green) and total num
50 μm. Percentage of TUNEL-positive nuclei was analyzed below. Data are expressed as meanconcentration by 46.7% (Fig. 6B, C). Similarly, inhibition of mitoJNK acti-
vation by 66.8% (Fig. 2B) could reduce lesion area by 32.6% and plasma
LDH concentration by 39.7% (Fig. 3A, B). These results indicated that
inhibitingmitoJNK activation alone could exert similar cardioprotective
effect as universal JNK inhibition.
Furthermore, treatment with anisomycin (0.1 mg/kg, administered
through contralateral femoral vein 15 min before reperfusion) which
activates JNK signaling abolished the cardioprotection of SP600125 in
I/R rats (Fig. 5B, C), further indicating that the cardioprotective effect
of SP600125 is through the inhibition of JNK activation.4. Discussion
The major ﬁndings of the present study are as follows. First, I/R in-
duces a dominant increase of mitoJNK activation which triggers Bcl2-
regulated autophagy and cytochrome c-mediated apoptosis. Second, it
is mitoJNK activation rather than JNK localization on mitochondria
that mediates the induction of I/R injury. Third, insulin selectively in-
hibits mitoJNK activation during reperfusion, which constitutes a
novel mechanism of insulin cardioprotection against I/R injury.
JNK has been shown to have an essential role inmodulating the func-
tions of pro- and anti-apoptotic proteins located in the mitochondria,
thus regulatingmitochondrial function andmitochondria-mediated apo-
ptosis [5,13,31]. However, previous studies lack evidence showing the
role of mitoJNK signaling in the regulation of mitochondrial function.
Until recently, with the aid of a new method to selectively inhibit
JNK translocation to mitochondria using Tat-SabKIM1 peptide through
inhibiting JNK interactingwith Sab, a binding partner for JNKmitochon-
drial association [9], LoGrasso and Chambers showed that mitoJNK sig-
naling mediated mitochondrial reactive oxygen species generation and
mitochondrial cytochrome c release [24]. Our in vivo study further con-
ﬁrmed that inhibition of mitoJNK activation with Tat-SabKIM1 reduced
mitochondrial cytochrome c release and thus reduced apoptosis andochondria-mediated apoptosis following I/R. A, levels of cytochrome c release (fold change
B, representative photomicrographs of in situ detection of apoptotic myocytes by TUNEL
ber of nuclei (blue) are shown for each representative section of the heart. Scale bar:
± SEM. n = 6/group. *P b 0.05, **P b 0.01.
Fig. 6.Universal JNK inhibition exerts cardioprotective effect against I/R injury similarly as inhibitingmitoJNK activation. A,myocardial phosphorylation level of JNK following I/R evaluated
by Western blot. B, myocardial infarct size (INF) expressed as percentage of area at risk (AAR) following I/R. C, plasma lactate dehydrogenase (LDH) concentration following I/R. SP
(SP600125, 1 mg/kg), a selective JNK inhibitor, was administered through femoral vein 10min before reperfusion. A (anisomycin, 0.1 mg/kg), a JNK activator, was administered through
contralateral femoral vein 15 min before reperfusion. Data are expressed as mean ± SEM. n = 6/group. *P b 0.05, **P b 0.01.
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that JNK mitochondrial localization was decreased, though activated
JNK on mitochondria was increased following I/R, which is contrary to
LoGrasso's results that I/R increased JNK localization on mitochondria
[19]. One possible reason for the discrepancy is that they only determined
the total JNK in both mitochondria and cytosol/nucleus in in vitro study.
Furthermore, our results showed that I/R induced a dominant increase
of mitoJNK activation rather than JNK activation in cytosol/nucleus.
mitoJNK activation caused cell death through not only cytochrome
c-mediated apoptosis but also Bcl2-regulated autophagy. Although the
precise role of autophagy regulation contributing to cell survival and
death in ischemic hearts remains controversial, a number of studies
have shown that despite the seemingly cardioprotective role of autopha-
gy during ischemia, autophagy can induce cell death during reperfusion
[20–22]. This form of cell death is referred to as type 2 programmed cell
death but may simply be caused by excessive activation of autophagy.
Mechanistically, mitoJNK phosphorylates Bcl2, antagonizing Bcl2 anti-
apoptotic and anti-autophagic activities [32,33], which may contribute
to mitoJNK's deleterious role in myocardial I/R injury. Other possible
mechanisms thatmaintain autophagy at a higher level during reperfusion
include oxidative stress, mitochondrial dysfunction, endoplasmic reticu-
lum stress and calcium overload [34].
Moreover, selective inhibition of mitoJNK activation produced simi-
lar infarct size-reducing effect as universally inhibiting JNKwith JNK in-
hibitor SP600125. This suggests that inhibition of mitoJNK activation
could possibly be at least partially responsible for the protective effects
of universal JNK inhibition against I/R. These results are potentially of
clinical signiﬁcance, and may suggest a new therapeutic strategy for
treating ischemic heart disease. Compounds that are either competitiveversus JNK-interacting protein or that have some bidentate character
might be achieved with therapeutic beneﬁt [35–37].
Studies from our laboratory and others demonstrate that the possible
mechanisms through which insulin attenuates cardiac ischemia injury
include metabolic modulation, positive inotropic effect and directly ac-
tivating survival signaling which exerts anti-apoptosis, vasodilatation,
anti-inﬂammation and anti-oxidative stress effects [38]. A lot of studies
have established that central to these effects is themitochondria whose
proper functioning is essential to myocardial health due to its vital role
in energy production and cell survival [28]. The present study showed
that treatment with insulin selectively inhibits mitoJNK activation,
although the exactmechanism is still elusive, consequently reduced ap-
optosis and infarct size. This extends our understanding of insulin
cardioprotection against I/R injury.
Based on the ﬁndings from previous studies and the present
study, we proposed a model illustrating the possible mechanism of
mitoJNK activation in the induction of myocardial I/R injury (Fig. 7).
JNK is activated at a relatively low level and localized in either mito-
chondria or cytosol/nucleus under unstressed condition. During I/R,
JNK is phosphorylated and activated JNK translocates to mitochondria,
resulting in increased mitoJNK activation. Increased mitoJNK activation
results in enhanced autophagy and cytochrome c release from mito-
chondria. Either insulin or Tat-SabKIM1 intervention inhibitsmitoJNK ac-
tivation and exerts cardioprotective effect against I/R injury.
In conclusion, this is the ﬁrst demonstration on the molecular level
that mitoJNK activation, rather than JNK mitochondrial localization, trig-
gers autophagy and apoptosis following I/R. InhibitingmitoJNK activation
with Tat-SabKIM1 peptide is as effective as inhibiting the catalytic activity
of universal JNK in improving post-ischemic cardiac function and
Fig. 7. Schematic ﬁgure illustrating that mitoJNK activation mediates myocardial I/R injury. TS: Tat-SabKIM1. The JNK locates in mitochondria and cytosol/nucleus in the absence of stress.
Once it confronted I/R, JNK is phosphorylated in cytosol/nucleus and activated JNK translocates to mitochondrial outer membrane which triggers Bcl2-regulated autophagy and
mitochondria-mediated apoptosis. Treatment with insulin or Tat-SabKIM1 inhibits mitoJNK activation and protects myocardium against I/R injury.
269J. Xu et al. / Biochimica et Biophysica Acta 1852 (2015) 262–270reducingmyocardial infarction.Moreover, insulin inhibitsmitoJNKactiva-
tion and thus reduces myocardial infarction, which constitutes a novel
mechanism of insulin cardioprotection against I/R injury. These results
suggest that strategies directed towards inhibiting mitochondria-
speciﬁc JNK activation may have therapeutic potential for ischemic
heart disease.
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